Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEHYDRATED ALCOHOL vs SOTRADECOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
FDA-approved for adjunctive therapy in the treatment of cystic thyroid nodules,Off-label: Neurolysis for celiac plexus block in pancreatic cancer pain,Off-label: Ablation of hepatocellular carcinoma,Off-label: Sclerotherapy for esophageal varices
Uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Small, uncomplicated varicose veins
Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.
0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
2-4 hours in most individuals at zero-order kinetics; terminal half-life is concentration-dependent due to saturation of alcohol dehydrogenase. Clinically, elimination rate is constant at 15-20 mg/d L/hour in non-tolerant individuals.
Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site
Primarily hepatic via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH); minor metabolism via CYP2E1 at high concentrations.
Sodium tetradecyl sulfate is primarily metabolized in the liver via sulfation and glucuronidation, with involvement of hepatic enzymes such as sulfotransferases and UDP-glucuronosyltransferases (UGTs).
Ethanol is primarily eliminated by hepatic metabolism (90-98%) via alcohol dehydrogenase and aldehyde dehydrogenase, with 2-10% excreted unchanged in urine, breath, and sweat. Renal elimination is minor and variable.
Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces
Negligible (<5%); no specific binding proteins.
>90% bound to plasma proteins, primarily albumin
0.5-0.7 L/kg, approximating total body water. Higher in females due to lower lean body mass.
0.15-0.3 L/kg; reflects limited distribution primarily to plasma and interstitial space
Oral: ~80-100% due to rapid absorption from stomach and small intestine; IV: 100%.
Not applicable; administered via intradermal, intravenous, or endoscopic injection; not intended for oral administration
No dosage adjustment required for renal impairment.
No specific dose adjustment provided in labeling; not studied in renal impairment; use caution in severe impairment.
No specific Child-Pugh-based adjustments; use with caution in severe hepatic dysfunction due to potential accumulation.
No specific dose adjustment provided in labeling; caution in Child-Pugh class C due to potential for acute hepatic necrosis.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Safety and efficacy not established in pediatric patients (age <18 years).
No specific dose adjustment; use with caution due to age-related comorbidities and potential for increased sensitivity.
No specific dose adjustment required; consider comorbidities and overall health status.
No FDA boxed warning exists for dehydrated alcohol. However, it should only be administered by physicians experienced in injection techniques for specific indications due to risk of tissue necrosis and nerve damage.
Sotradecol injection is contraindicated for the treatment of patients with underlying arterial disease or with known allergy to the drug. Severe adverse reactions including anaphylaxis, pulmonary embolism, and tissue necrosis have been reported.
Risk of tissue necrosis and sloughing if extravasation occurs,Neurological injury if injected near nerves (e.g., peripheral nerve damage, paralysis),Hypotension and bradycardia during celiac plexus block,Alcohol intoxication and CNS depression if absorbed systemically,Use with caution in patients with liver disease or diabetes mellitus
Anaphylactic reactions; arterial injection causing tissue necrosis; pulmonary embolism; allergy to the drug; use with caution in patients with thrombophlebitis, hypercoagulable states, or chronic obstructive pulmonary disease; avoid extravasation.
Hypersensitivity to ethanol or any component of the formulation,Acute infection at the injection site,Uncorrectable coagulation abnormalities,Pregnancy (relative contraindication due to fetal alcohol spectrum disorders)
Known allergy to sodium tetradecyl sulfate; acute thrombophlebitis; severe chronic venous insufficiency; arterial disease; uncontrolled diabetes mellitus; sepsis; pregnancy; breastfeeding; incompetent perforating veins.
No specific food interactions. However, avoid alcohol consumption for 24 hours post-procedure due to risk of additive CNS depression.
No specific food interactions are known. Patients should maintain adequate hydration and avoid excessive alcohol intake, which may increase the risk of bleeding or thrombosis. No dietary restrictions are required.
First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) with high systemic exposure. Second trimester: Continued risk for growth restriction and neurodevelopmental abnormalities. Third trimester: Risk of growth retardation, preterm birth, and neurobehavioral deficits. Avoid systemic use; local injection for nerve block or ablation has minimal systemic absorption but caution advised.
FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third trimester: risk of fetal bradycardia, arrhythmias, or death due to systemic absorption if injected near cervix.
Alcohol is excreted into breast milk; M/P ratio approximately 1.0. Chronic ingestion can impair infant motor development. Dehydrated alcohol for therapeutic injection likely results in negligible systemic levels; however, avoid breastfeeding immediately after procedure. Advise discarding milk for 2-3 hours post-procedure.
Unknown excretion in human milk. Due to low systemic absorption after local injection, risk to breastfed infant is likely low. Caution recommended; M/P ratio not established.
No dose adjustment needed for localized injection; pharmacokinetics of ethanol unchanged in pregnancy. Avoid use as systemic agent; use alternative if possible.
No dose adjustment required; however, use only when clearly needed. Systemic absorption is minimal after local injection, and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety.
Absolute ethanol (dehydrated alcohol) is used for neurolysis in celiac plexus block for pancreatic cancer pain and for ablation of certain soft tissue lesions. Administer slowly to avoid local toxicity. Inadvertent intravascular injection can cause immediate pain and tissue necrosis. Use ultrasound or CT guidance for accurate placement. Monitor for hypotension, pain, and transient alcohol intoxication. Contraindicated in patients with bleeding disorders or local infection.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent used for the treatment of varicose veins. Administer via direct injection into the vein using a fine needle; avoid extravasation as it causes tissue necrosis. Perform a test dose (0.5 m L) to assess for hypersensitivity. Compression stockings should be worn for 1-3 weeks post-injection. Do not exceed 10 m L per session; maximum total dose per session is 10 m L of 1% or 2 m L of 3% solution. Use caution in patients with arterial disease, recent thrombosis, or known hypersensitivity. Delayed skin pigmentation may occur. Allergic reactions, including anaphylaxis, have been reported.
You may feel a temporary burning sensation at the injection site.,This medication is used to block pain signals from certain nerves.,Avoid alcohol consumption for 24 hours after the procedure to prevent additive effects.,Report any severe pain, bleeding, or signs of infection to your healthcare provider.,You may experience temporary dizziness or lightheadedness after the injection.
This medication is injected directly into your varicose veins to cause them to collapse and fade.,You may experience a burning sensation at the injection site, which is normal.,Wear compression stockings as directed, typically for 1-3 weeks after treatment.,Avoid strenuous exercise and prolonged standing for 24-48 hours after injection.,Contact your doctor if you develop severe pain, swelling, redness, or skin ulcers at the injection site.,Notify your doctor if you have a history of blood clots, allergies, or are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEHYDRATED ALCOHOL vs SOTRADECOL, answered by our medical review team.
DEHYDRATED ALCOHOL is a Sclerosing agent that works by Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.. SOTRADECOL is a Sclerosing agent that works by Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEHYDRATED ALCOHOL and SOTRADECOL depend on the specific clinical indication. These are both Sclerosing agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEHYDRATED ALCOHOL is: Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.. The standard adult dose of SOTRADECOL is: 0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEHYDRATED ALCOHOL and SOTRADECOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEHYDRATED ALCOHOL is classified as Category C. First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) wit. SOTRADECOL is classified as Category C. FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.